February 10, 2023 06:22 AM ESTUpdated 11:24 AM
Financing
Startups

IPO Fri­day: Hy­per­ten­sion drug­mak­er Min­eralys maps out $192M Nas­daq de­but

Kyle LaHucik

Senior Reporter

Wall Street is wel­com­ing a new drug de­vel­op­er to the stock mar­kets for the sec­ond Fri­day in a row.

Min­eralys Ther­a­peu­tics

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump picks vac­cine skep­tic Kennedy to lead HHS, in what would be an up­heaval of US health pol­i­cy

Eu­ro­pean drug reg­u­la­tor re­vers­es opin­ion on Ei­sai and Bio­gen's Alzheimer's drug

Gilead will close Philadel­phia, Seat­tle of­fices as part of job re­duc­tions

BeiGene will re­brand to BeOne Med­i­cines, drop­ping name's link to Chi­na roots

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times